New York Life Investment Management LLC Purchases 205 Shares of Humana Inc. (NYSE:HUM)

New York Life Investment Management LLC raised its position in shares of Humana Inc. (NYSE:HUM) by 1.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 18,049 shares of the insurance provider’s stock after purchasing an additional 205 shares during the period. New York Life Investment Management LLC’s holdings in Humana were worth $4,579,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also bought and sold shares of the company. State Street Corp grew its holdings in Humana by 1.0% during the third quarter. State Street Corp now owns 5,357,420 shares of the insurance provider’s stock valued at $1,701,582,000 after purchasing an additional 53,272 shares during the period. FMR LLC grew its holdings in Humana by 23.4% during the third quarter. FMR LLC now owns 3,388,859 shares of the insurance provider’s stock valued at $1,073,387,000 after purchasing an additional 643,291 shares during the period. Pzena Investment Management LLC grew its holdings in Humana by 8.1% during the third quarter. Pzena Investment Management LLC now owns 2,506,250 shares of the insurance provider’s stock valued at $793,830,000 after purchasing an additional 187,903 shares during the period. Ontario Teachers Pension Plan Board grew its holdings in Humana by 6.5% during the third quarter. Ontario Teachers Pension Plan Board now owns 1,173,535 shares of the insurance provider’s stock valued at $371,705,000 after purchasing an additional 71,910 shares during the period. Finally, Sanders Capital LLC grew its holdings in Humana by 1.0% during the third quarter. Sanders Capital LLC now owns 1,168,341 shares of the insurance provider’s stock valued at $370,060,000 after purchasing an additional 11,923 shares during the period. 92.38% of the stock is owned by institutional investors.

Insider Activity

In other news, insider Timothy S. Huval sold 3,703 shares of the business’s stock in a transaction dated Tuesday, December 31st. The stock was sold at an average price of $256.26, for a total value of $948,930.78. Following the completion of the sale, the insider now owns 8,181 shares of the company’s stock, valued at approximately $2,096,463.06. The trade was a 31.16 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 0.32% of the stock is currently owned by corporate insiders.

Humana Trading Up 3.6 %

Shares of HUM stock opened at $270.91 on Friday. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.68. The business has a 50-day moving average price of $271.11 and a two-hundred day moving average price of $287.34. Humana Inc. has a 12-month low of $213.31 and a 12-month high of $406.46. The firm has a market cap of $32.68 billion, a P/E ratio of 27.23, a price-to-earnings-growth ratio of 2.05 and a beta of 0.56.

Humana (NYSE:HUM) last issued its quarterly earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.26) by $0.10. Humana had a return on equity of 11.70% and a net margin of 1.02%. Equities analysts anticipate that Humana Inc. will post 16.47 EPS for the current fiscal year.

Humana Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, April 25th. Stockholders of record on Friday, March 28th will be paid a $0.885 dividend. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.31%. The ex-dividend date of this dividend is Friday, March 28th. Humana’s dividend payout ratio (DPR) is presently 35.58%.

Analyst Upgrades and Downgrades

HUM has been the subject of a number of analyst reports. Piper Sandler raised their price target on Humana from $270.00 to $288.00 and gave the stock a “neutral” rating in a report on Wednesday, January 15th. Bank of America raised Humana from an “underperform” rating to a “neutral” rating and raised their price target for the stock from $247.00 to $308.00 in a report on Wednesday, November 6th. StockNews.com raised Humana from a “hold” rating to a “buy” rating in a report on Tuesday. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $283.00 price target on shares of Humana in a report on Wednesday, February 12th. Finally, Barclays raised their price target on Humana from $255.00 to $270.00 and gave the stock an “equal weight” rating in a report on Thursday, February 13th. Nineteen analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $285.68.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.